Life Science

D-erythro-Sphingosine is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatic acid phosphohydrolase, whereas it activates PLD and DAG kinase.

D-erythro-Sphingosine is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatic acid phosphohydrolase, whereas it activates PLD and DAG kinase.

D-erythro-Sphingosine is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatic acid phosphohydrolase, whereas it activates PLD and DAG kinase.

D-erythro-Sphingosine is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatic acid phosphohydrolase, whereas it activates PLD and DAG kinase.

Composes a significant portion of CNS gangliosides concentration increases with maturation and may be related to nervous system degeneration.

Composes a significant portion of CNS gangliosides concentration increases with maturation and may be related to nervous system degeneration.

Composes a significant portion of CNS gangliosides concentration increases with maturation and may be related to nervous system degeneration.

Composes a significant portion of CNS gangliosides concentration increases with maturation and may be related to nervous system degeneration.

MolecularFormula : C6H11O9PK2 Molecular Weight : 336.32 Purity Limit : &gt 95% Purity Limit : &gt 95% Storage Temp : Store at -20 &degC Appearance : White Solid

MolecularFormula : C6H11O9PK2 Molecular Weight : 336.32 Purity Limit : &gt 95% Purity Limit : &gt 95% Storage Temp : Store at -20 &degC Appearance : White Solid

A fundamental component of glucose metabolism involved in the homeostatic regulation of blood glucose levels by participating in glycolysis, glycogen synthesis, and gluconeogenesis.

A fundamental component of glucose metabolism involved in the homeostatic regulation of blood glucose levels by participating in glycolysis, glycogen synthesis, and gluconeogenesis.